It would make sense to sell a large stake in the diagnostic division with profit split on revenue. That would give AMBS much needed up front money for Eltoprazine and MANF plus future revenue and profit split. However, it sounds like they have many options that are being presented in regard to the Dx Division. No matter what happens there will be revenue from 2 products in 2015 and MSPrecise sounds large in the near term.